Study identification

PURI

https://redirect.ema.europa.eu/resource/48247

EU PAS number

EUPAS17919

Study ID

48247

Official title and acronym

Abacavir Usage Patterns and Trends in Hypersensitivity Reactions (HSR) in the EuroSIDA cohort (206307)

DARWIN EU® study

No

Study countries

Argentina
Austria
Belarus
Belgium
Bulgaria
Croatia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Ireland
Israel
Italy
Latvia
Lithuania
Luxembourg
Netherlands
Norway
Poland
Portugal
Romania
Russian Federation
Serbia
Slovakia
Spain
Sweden
Switzerland
Ukraine
United Kingdom

Study status

Finalised
Research institutions and networks

Institutions

ViiV Healthcare
First published:
01/02/2024
Institution

Contact details

GSK Clinical Disclosure Advisor GSK Clinical Disclosure Advisor

Study contact

GSK Clinical Disclosure Advisor GSK Clinical Disclosure Advisor

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

ViiV Healthcare
Study protocol
Initial protocol
English (392.93 KB - PDF)View document
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable